HOME >> BIOLOGY >> NEWS
Liver transplant patients gain same benefits from CellCept as kidney transplant patients

25th May 2005, Basel, Switzerland New data reported in over 90 abstracts presented at the American Transplant Congress in Seattle show that liver transplant patients taking the immunosuppressant CellCept are gaining the same positive benefits already demonstrated in kidney transplant patients. This is good news for patients as the demand for liver transplants is increasing, with many of the cases directly resulting from chronic hepatitis C virus (HCV) infection.

Benefits seen with CellCept include:

  • Reduced risk of acute rejection, especially in patients infected with HCV
    • graft rejection is of particularly high risk in HCV patients and is associated with increased morbidity and decreased patient and graft survival (Abstract 928)

  • Safe and effective steroid-free regimens for HCV patients
    • steroids are known to have a negative impact on the progression of HCV, which can result in liver fibrosis (Abstract 475)

  • Optimal kidney function
    • CellCept taken with a low dose of tacrolimus showed a trend towards improved kidney function (Abstract 1240). CellCept is proven to promote excellent kidney function early after kidney transplantation in renal patients taking tacrolimus(1)

  • Less liver fibrosis
    • recipients taking CellCept-based regimens showed a significant reduction in the inflammation and structural changes that can lead to liver failure (Abstract 1446)

  • No increased risk of malignancy
    • the addition of CellCept to maintenance immunosuppression that includes tacrolimus and corticosteroids did not increase the risk of death due to malignant complications (Abstract 930). This confirms previous data as seen in kidney transplant recipients(2)

"It's really exciting to see liver transplant recipients benefiting from CellCept in the same way as kidney transplant patients.
'"/>

Contact: Vicky Singlehurst
vicky.singlehurst@ketchum.com
+44-207-611-3523
Ketchum
25-May-2005


Page: 1 2

Related biology news :

1. Liverpool amongst first in UK to install unique DNA sequencing technology
2. University of Liverpool launches 10 million small animal teaching hospital
3. Liverpool scientists work to improve water quality in Ghana
4. Liver regeneration may be simpler than previously thought
5. 2.5M boost for marine biology in Liverpool
6. Liver signal critical for insulins brain action
7. International scientists to present MRSA research in Liverpool
8. UC Davis, Lawrence Livermore researchers
9. Liver cancer linked to cellular repair pathway
10. Liver metabolism goes to pot
11. Liverpool vet creates pain relief diet for arthritic dogs

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:5/6/2017)... RAM Group , Singaporean based ... in biometric authentication based on a novel  ... to perform biometric authentication. These new sensors are based on ... Ram Group and its partners. This sensor will have ... and security. Ram Group is a next generation ...
(Date:4/17/2017)... 2017 NXT-ID, Inc. (NASDAQ: NXTD ) ... of its 2016 Annual Report on Form 10-K on Thursday April ... ... in the Investor Relations section of the Company,s website at ... at http://www.sec.gov . 2016 Year Highlights: ...
(Date:4/11/2017)... , Apr. 11, 2017 Research and Markets ... 2017-2021" report to their offering. ... The global eye tracking market to grow at a CAGR ... Global Eye Tracking Market 2017-2021, has been prepared based on an ... the market landscape and its growth prospects over the coming years. ...
Breaking Biology News(10 mins):
(Date:10/11/2017)... CA, USA (PRWEB) , ... October 11, 2017 , ... ... to take place on 7th and 8th June 2018 in San Francisco, CA. The ... influencers as well as several distinguished CEOs, board directors and government officials from around ...
(Date:10/11/2017)... , ... October 11, 2017 , ... ... the implantation and pregnancy rates in frozen and fresh in vitro fertilization ... progesterone and maternal age to IVF success. , After comparing the results from ...
(Date:10/10/2017)... ... ... Dr. Bob Harman, founder and CEO of VetStem Biopharma, Inc. ... event entitled “Stem Cells and Their Regenerative Powers,” was held on August 31st, ... was joined by two human doctors: Peter B. Hanson, M.D., Chief of Orthopedic Surgery, ...
(Date:10/9/2017)... , Oct. 9, 2017  BioTech Holdings ... mechanism by which its ProCell stem cell therapy ... limb ischemia.  The Company, demonstrated that treatment with ... of limbs saved as compared to standard bone ... molecule HGF resulted in reduction of therapeutic effect.  ...
Breaking Biology Technology:
Cached News: